title: Towards universal ARV access: achievements and challenges in Free State Province, South Africa.
abstract: OBJECTIVE
  To study the progress and challenges with regard to universal antiretroviral (ARV) access in Free State Province, South Africa.
  
  
  METHODS
  Data from the first 4 years of the public sector ARV roll-out and selected health system indicators were used. Data were collected from the public sector ARV database in Free State Province for new patients on ARVs, average waiting times and median CD4 counts at the start of treatment. Information on staff training, vacancy rates and funding allocations for the ARV roll-out was obtained from official government reports. Projections were made of expected new ARV enrolments for 2008 and 2009 and compared with goals set by the National Strategic Plan (NSP) to achieve universal access to ARVs by 2011.
  
  
  RESULTS
  New ARV enrolments increased annually to 25% of the estimated need by the end of 2007. Average waiting times to enrolment decreased from 5.82 months to 3.24 months. Median CD4 counts at enrolment increased from 89 to 124 cells/mm3. There is a staff vacancy rate of 38% in the ARV programme and an inadequate increase in budget allocations.
  
  
  CONCLUSIONS
  The current vertical model of ARV therapy delivery is unlikely to raise the number of new enrolments sufficiently to achieve the goals of universal access by 2011 as envisaged by the NSP. The Free State is implementing a project (STRETCH trial) to broaden the ARV roll-out in an attempt to increase access to ARVs.
authors.affiliation: Knowledge Translation Unit, UCT Lung Institute, Cape Town. uebelke@fshealth.gov.za
authors.forename: Kerry E
authors.initials: KE
authors.lastname: Uebel
authors.forename: Venessa
authors.initials: V
authors.lastname: Timmerman
authors.forename: Suzanne M
authors.initials: SM
authors.lastname: Ingle
authors.forename: Dingie H C J
authors.initials: DH
authors.lastname: van Rensburg
authors.forename: Willie F
authors.initials: WF
authors.lastname: Mollentze
mesh_terms: D000293:Adolescent; D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D001071:Appointments and Schedules; D018791:CD4 Lymphocyte Count; D003140:Communicable Disease Control / Q000706:statistics & numerical data* / Q000639:trends; D015658:HIV Infections / Q000453:epidemiology / Q000517:prevention & control*; D006291:Health Policy; D006297:Health Services Accessibility / Q000706:statistics & numerical data* / Q000639:trends; D006801:Humans; D015994:Incidence; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D012189:Retrospective Studies; D013019:South Africa / Q000453:epidemiology; D055815:Young Adult
chemical_list: D044966:Anti-Retroviral Agents